Rian Van Rampelbergh

3.0k total citations
15 papers, 111 citations indexed

About

Rian Van Rampelbergh is a scholar working on Hematology, Genetics and Surgery. According to data from OpenAlex, Rian Van Rampelbergh has authored 15 papers receiving a total of 111 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 6 papers in Genetics and 5 papers in Surgery. Recurrent topics in Rian Van Rampelbergh's work include Inflammatory Bowel Disease (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Microscopic Colitis (4 papers). Rian Van Rampelbergh is often cited by papers focused on Inflammatory Bowel Disease (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Microscopic Colitis (4 papers). Rian Van Rampelbergh collaborates with scholars based in Belgium, United States and Netherlands. Rian Van Rampelbergh's co-authors include Rik Schots, Hendrik De Raeve, Karine Breckpot, Kim De Veirman, Nathan De Beule, Karin Vanderkerken, Ken Maes, Eline Menu, Els Van Valckenborgh and Jo A. Van Ginderachter and has published in prestigious journals such as Blood, Gastroenterology and The American Journal of Gastroenterology.

In The Last Decade

Rian Van Rampelbergh

12 papers receiving 108 citations

Peers

Countries citing papers authored by Rian Van Rampelbergh

Since Specialization

Citations

This map shows the geographic impact of Rian Van Rampelbergh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rian Van Rampelbergh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rian Van Rampelbergh more than expected).

Fields of papers citing papers by Rian Van Rampelbergh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rian Van Rampelbergh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rian Van Rampelbergh. The network helps show where Rian Van Rampelbergh may publish in the future.

Co-authorship network of co-authors of Rian Van Rampelbergh

This figure shows the co-authorship network connecting the top 25 collaborators of Rian Van Rampelbergh. A scholar is included among the top collaborators of Rian Van Rampelbergh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rian Van Rampelbergh. Rian Van Rampelbergh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	P0669 Safety of intravenous and subcutaneous guselkumab induction administration: Results from the GALAXI and GRAVITI studies in participants with Crohn’s Disease 2025 ·Journal of Crohn s and Colitis ·Silvio Danese, Bruce E. Sands, Anita Afzali, Tadakazu Hisamatsu, Alessandro Armuzzi, Douglas C. Wolf, (unknown), Rian Van Rampelbergh, Mobolaji Olurinde, Natalie A. Terry, Jacqueline Yee, Li Huang, (unknown), Geert D’Haens, David T. Rubin, (unknown)	1
2	P0608 Safety of guselkumab in Inflammatory Bowel Disease up to 1 year: Integrated safety analysis of phase 2 and 3 studies in Crohn’s Disease and Ulcerative Colitis 2025 ·Journal of Crohn s and Colitis ·B E Sands, Remo Panaccione, Silvio Danese, Julián Panés, Takashi Hisamatsu, Geert D’Haens, Rian Van Rampelbergh, Mobolaji Olurinde, Jacqueline Yee, Thomas Baker, Shadi Yarandi, Matthew Germinaro, Monica L. Vetter, Li Huang, (unknown), Jessica R. Allegretti, Anita Afzali, David T. Rubin	1
3	P0917 Corticosteroid sparing effects of treatment with guselkumab in patients with moderate to severely active Crohn’s disease: Phase 3 GALAXI 2/3 results through week 48 2025 ·Journal of Crohn s and Colitis ·Julián Panés, Tadakazu Hisamatsu, Alessandro Armuzzi, Natalie A. Terry, Leonardo Salese, Rian Van Rampelbergh, Jacqueline Yee, Kitty Y. Wan, Zijiang Yang, (unknown), Bruce E. Sands, David T. Rubin	2
4	DOP060 Early disease efficacy of guselkumab therapy in biologic-naïve patients with moderately to severely active Crohn’s disease: Post-hoc analysis from the phase 3 GALAXI 2 & 3 studies 2025 ·Journal of Crohn s and Colitis ·Anita Afzali, David T. Rubin, Silvio Danese, Yaser Rayyan, Min Chen, Natalie A. Terry, Leonardo Salese, Rian Van Rampelbergh, Jacqueline Yee, Mario Gómez, Kitty Y. Wan, Zijiang Yang, B E Sands, Geert D’Haens	3
5	Comparison of vaccine-induced immune thrombocytopenia and thrombosis cases following two adenovirus-vectored COVID-19 vaccines 2025 ·Communications Medicine ·Rian Van Rampelbergh, Sue Pavord, (unknown), (unknown), Karin Hardt, Erhan Tatar, Javier Ruiz‐Guiñazú, Dennis J Baumgardner, (unknown), Nicolas Praet, Hendy Kristyanto, Jerald Sadoff, Macaya Douoguih, Yimei Xu, Frank Struyf	1
6	Su1853: EFFICACY OF GUSELKUMAB INTRAVENOUS AND SUBCUTANEOUS INDUCTION: SYMPTOMS, HEALTH-RELATED QUALITY OF LIFE, AND INFLAMMATORY BIOMARKER RESULTS FROM THE GALAXI AND GRAVITI STUDIES 2025 ·Gastroenterology ·(unknown), Remo Panaccione, (unknown), Tadakazu Hisamatsu, Geert D’Haens, Natalie A. Terry, Mobolaji Olurinde, Rian Van Rampelbergh, Leonardo Salese, Elizabeth Merrall, Kitty Y. Wan, Zijiang Yang, Bruce E. Sands, (unknown)	0
7	EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIES 2024 ·Gastroenterology ·Remo Panaccione, Silvio Danese, Brian G. Feagan, Geert D’Haens, (unknown), Walter Reinisch, Julián Panés, David T. Rubin, Jane M. Andrews, Tadakazu Hisamatsu, Natalie A. Terry, Leonardo Salese, Rian Van Rampelbergh, Mary Ellen Frustaci, Zijiang Yang, Jewel Johanns, Kitty Y. Wan, Jacqueline Yee, Bruce E. Sands	22
8	S1445 Efficacy of Guselkumab vs Placebo in Crohn’s Disease Based on Prior Response/Exposure to Biologic Therapy: Results of the GALAXI 2 and 3 Phase 3 Studies 2024 ·The American Journal of Gastroenterology ·Bruce E. Sands, Geert D’Haens, Silvio Danese, Tadakazu Hisamatsu, Walter Reinisch, Natalie A. Terry, Leonardo Salese, Rian Van Rampelbergh, Zijiang Yang, Jewel Johanns, (unknown), Niazy Abu Farsakh, (unknown)	1
9	S1053 Week 48 Efficacy Of Guselkumab And Ustekinumab In Crohn’s Disease Based On Prior Response/Exposure To Biologic Therapy: Results From The GALAXI 2 and 3 Phase 3 Studies 2024 ·The American Journal of Gastroenterology ·Silvio Danese, Anita Afzali, Remo Panaccione, Julián Panés, Walter Reinisch, Natalie A. Terry, Leonardo Salese, Rian Van Rampelbergh, Kitty Y. Wan, Zijiang Yang, Jewel Johanns, (unknown), Eran Zittan, Katsuyoshi Matsuoka, Vipul Jairath, David T. Rubin	0
10	Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S 2023 ·Vaccine ·Frank Struyf, Karin Hardt, Rian Van Rampelbergh, Georgi Shukarev, (unknown), Javier Ruiz‐Guiñazú, (unknown), (unknown), (unknown), (unknown), Vicky Cárdenas, Gerald A. Soff, (unknown), Jerald Sadoff, Macaya Douoguih	3
11	OAB-039: Treatment duration and long-term outcomes with daratumumab in transplant-ineligible newly diagnosed multiple myeloma from the phase 3 MAIA study 2022 ·Clinical Lymphoma Myeloma & Leukemia ·Philippe Moreau, Thierry Façon, Saad Z. Usmani, Shaji Kumar, Torben Plesner, Hartmut Goldschmidt, Robert Z. Orlowski, Aurore Perrot, Ajai Chari, Gordon Cook, Huiling Pei, Rian Van Rampelbergh, J. Blake Bartlett, Clarissa Uhlar, Richard G. Carson, Nizar J. Bahlis	0
12	Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma 2022 ·Journal of Oncology Pharmacy Practice ·María‐Victoria Mateos, Sophie Rigaudeau, Supratik Basu, Ivan Špıčka, Rik Schots, Tomasz Wróbel, Gordon Cook, Meral Beksaç, Katharine S. Gries, Anupa Kudva, Brenda Tromp, Rian Van Rampelbergh, Huiling Pei, Susan Wróblewski, Robin Carson, Maria Delioukina, Darrell White	10
13	Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study 2020 ·Advances in Therapy ·Jianming He, (unknown), Rian Van Rampelbergh, Lugui Qiu, Ravi Potluri, (unknown), Lin Li, Yunan Li, Peter Hu, (unknown), Steven S. Smugar, Paul M. Zeltzer, (unknown), Qing Li, Maneesha Mehra, Ute Richarz	8
14	Predictive Markers of High-Grade or Serious Treatment-Emergent Infections with Daratumumab-Based Regimens in Newly Diagnosed Multiple Myeloma (NDMM) 2020 ·Blood ·Niels W.C.J. van de Donk, Sonja Zweegman, Jesús F. San Miguel, Meletios Α. Dimopoulos, Michèle Cavo, Kenshi Suzuki, Cyrille Touzeau, Saad Z. Usmani, Aurore Perrot, Huiling Pei, Anupa Kudva, Rian Van Rampelbergh, Jon Ukropec, (unknown), Robin Carson, Ming Qi, Ajai Chari	6
15	Tumour‐associated macrophage‐mediated survival of myeloma cells through STAT3 activation 2016 ·The Journal of Pathology ·Nathan De Beule, Kim De Veirman, Ken Maes, Elke De Bruyne, Eline Menu, Karine Breckpot, Hendrik De Raeve, Rian Van Rampelbergh, Jo A. Van Ginderachter, Rik Schots, Els Van Valckenborgh, Karin Vanderkerken	53

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact